The size of global Carrier Screening Market in terms of revenue was estimated to be worth $2.2 Billion in 2023 and is poised to reach $5.4 Billion by 2028, growing at a CAGR of 19.7% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
The expansion of this market is majorly due to the development and availability of expanded carrier screening panels that cover a wide range of genetic conditions contribute to the market's growth. Comprehensive panels offer more thorough assessments, and healthcare providers adopt them to provide more extensive genetic information to patients. However, Despite efforts to increase awareness, many individuals and healthcare professionals may still have limited knowledge about the availability and importance of carrier screening. Lack of awareness can contribute to underutilization of carrier screening services which may inhibit the growth of this market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72642285
Key Market
The major players in the Carrier Screening Assays Market are
- Invitae Corporation.(US) ,
- Fulgent Genetics.(US),
- Eurofins Scientific (Germany),
- OPKO Health, Inc.(US),
- Thermo Fisher Scientific Inc.(US),
- Quest Diagnostics Incorporated (US),
- Myriad Genetics, Inc (US),
- Illumina, Inc.(US),
- Natera, Inc.(Italy),
- Laboratory Corporation of America Holdings.(US),
- CENTOGENE N.V.(Germany), and
- DiaSorin S.p.A.(Italy)
DRIVER: the increasing prevalence of genetic disorders
The rising prevalence and awareness of genetic diseases contribute significantly to the growth and demand in the carrier screening market. Carrier screening is a crucial tool for identifying individuals who carry a single copy of a gene mutation associated with a specific genetic disorder.
There are an estimated 10,000 different types of single-gene diseases (also called monogenic diseases), which are diseases caused by mutations in a single gene. The World Health Organization estimates that 10 out of every 1000 people are affected. This means that between 70 million and 80 million people in the world are living with one of these diseases. Similarly, as per the NIH, around 350 million people are living with rare disorders, and this is a disorder or condition with fewer than 200,000 people diagnosed. About 80% of these rare disorders are genetic in origin, and 95% of them do not have even one treatment approved by the FDA. In addition, as per a new scientific paper published in the European Journal of Human Genetics has confirmed that the number of people worldwide living with a rare disease is estimated at 300 million.
In addition, the rising prevalence of hereditary cancer is indeed a significant driver for the market. Carrier screening, particularly for cancer susceptibility genes, plays a crucial role in identifying individuals who carry genetic mutations associated with an increased risk of developing certain types of cancer. For instance, as per the NIH, up to 10% of all cancers may cause by inherited genetic changes. As a result, The rising prevalence of genetic diseases underscores the importance of carrier screening as a preventive measure and a tool for informed decision-making in family planning. As awareness continues to grow the market is likely to play an increasingly crucial role in managing and preventing genetic diseases.
Inquiry Before Buying @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=72642285
RESTRAINT: high cost of carrier screening
The high cost of carrier screening can indeed be a significant restraint for market growth. The affordability and accessibility of genetic testing services, including carrier screening, are key factors that influence the adoption of these services by individuals, couples, and healthcare providers. High costs may limit access to carrier screening services for individuals and couples with limited financial means. This can result in disparities in healthcare, where only those who can afford the testing may benefit, creating inequities in access. Similarly, the high cost of carrier screening may lead to reduced adoption rates, as individuals and couples may be deterred by the financial burden associated with undergoing the testing. This can impact the overall uptake of carrier screening services.
For instance, the Centers for Medicare & Medicaid Services, or CMS, establishes payment levels and coverage rules under Medicare, while state Medicaid programs and commercial health plans establish rates and coverage rules independently in accordance with applicable rules. As such, the reimbursement rates for our diagnostic tests vary by third-party payer. CMS has established a pricing benchmark of USD 2,450 for expanded carrier screening testing. Similarly, as per the article published by obstetrics & Gynecology 2023, the price of 22 panels ranged from USD 349 to USD 4320 per couple in USD.
As a result, High costs may influence consumer perception and acceptance of carrier screening. Individuals and couples may question the value proposition of the testing in relation to the associated financial investment which can cause a threat to market growth.
OPPORTUNITY: integration with telehealth and digital health platforms
The integration of telehealth and digital health platforms creates significant opportunities within the market. Leveraging digital technologies enhances accessibility, improves the efficiency of genetic testing services, and contributes to a more patient-centered approach. Telehealth platforms enable individuals, especially those in remote or underserved areas, to access carrier screening services without the need to visit a physical healthcare facility. This increased accessibility helps reach a broader population. Similarly, telehealth platforms allow for the provision of preconception and prenatal care services, including carrier screening consultations. This supports individuals and couples in making decisions about family planning and managing genetic risks during pregnancy. In addition, Digital health platforms support ongoing follow-up care after carrier screening. This includes virtual consultations, monitoring of genetic risks, and the development of personalized care plans based on screening results. One of the recent developments in this segment is as below:
In 2022, Ambry Genetics (Ambry), a clinical diagnostic testing and a subsidiary of REALM IDx, launched a new reproductive health program that is driven by its CARE ProgramTM (Comprehensive Assessment Risk and Education), a digital platform that enhances the patient and provider experience through easier access to genetic education, testing, reporting, and counseling. This end-to-end program improves family planning and prenatal care by expanding access to carrier screening and NIPT, also known as non-invasive prenatal screening (NIPS), and by helping patients make informed decisions. NIPT is for screening, not diagnosis.
Request Free Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=72642285
China is anticipated to account the second largest share of Apac Region of Carrier Screening Industry
Based on the Apac region, the Carrier Screening Market is divided into China, Japan, and India. China is expected to account the largest share of Market. This is due to the Growing awareness among the Chinese population about genetic disorders and the importance of carrier screening is a key driver. Educational initiatives and campaigns can contribute to increased demand for carrier screening services and increased healthcare spending in China which lead to improved access to advanced medical technologies, including carrier screening. In addition, The prevalence of genetic disorders in the Chinese population can drive the demand for carrier screening.
Germany is forecasted as the fastest growing country of Carrier Screening Industry in Europe.
Based on the Europe region, the Carrier Screening Market is divided into Germany, UK, Italy, Spain, France, and RoE. Germany is forecasted to be the fastest growing market of Market in Europe. Germany is known for its strong biomedical research community, including leading universities, research institutes, and healthcare facilities. The country’s commitment to scientific research contributes to the demand for advanced diagnostic technologies like carrier screening. In addition, Germany has a robust healthcare infrastructure, which includes advanced laboratories and diagnostic facilities. The availability of well-equipped healthcare institutions supports the implementation and utilization of sophisticated diagnostic technologies such as carrier screening.
North America dominates the global Carrier Screening Industry
Based on the region, the Carrier Screening Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to dominate the Carrier Screening assay market. Growth in the North American market is mainly driven by the factors such as North America, boasts an advanced and well-established healthcare infrastructure. The presence of state-of-the-art laboratories, research institutions, and healthcare facilities provides a conducive environment for the adoption of advanced diagnostic technologies like carrier screening. Similarly, The region is home to some of the world’s leading research institutions and academic centers. These institutions are often at the forefront of genetic research, including studies related to rare diseases, driving the demand for carrier screening services.
Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=72642285
Recent Developments of Carrier Screening Industry:
- In 2022, OPKO Health Acquired ModeX Therapeutics, to gain Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
- In 2021, DiaSorin acquired Luminex Corporation to expands DiaSorin’s offer in the molecular diagnostic sector gaining access to multiplexing technology, which allows analysis of multiple parameters from a single biological sample within a single run.
